Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/63—Steroids; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9794—Liliopsida [monocotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
  • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

• the invention relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the signs of skin aging, in particular the loss of elasticity and / or tone of the skin, by inhibition of collagenase activity.
• It also relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the loss of firmness of the human skin of the face and / or of the neck.
• Human skin is made up of two compartments, namely a surface compartment, the epidermis, and a deep compartment, the dermis.
• the natural human epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
• the dermis provides the epidermis with solid support. It is also its nourishing element.
• H consists mainly of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, called the fundamental substance, components synthesized by the fibroblast.
• leukocytes There are also leukocytes, mast cells or tissue macrophages. It is also crossed by blood vessels and nerve fibers.
• Collagen fibers which ensure the solidity of the dermis.
• Collagen fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures.
• the solidity of the dermis is largely due to the good quality entanglement of collagen fibers packed against each other in all directions. Collagen fibers participate in the firmness, elasticity and tone of the skin and / or mucous membranes.
• the collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis.
• various factors cause collagen to degrade, with all the consequences that can be expected on the structure and / or firmness of the skin and / or mucous membranes.
• collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that humans, preferring the appearance of smooth and taut skin, have always sought to combat.
• Collagenases are part of a family of enzymes called metalloproteinases (MMPs) - which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and the basal laminae at neutral pH (collagen, elastin, etc.).
• MMPs metalloproteinases
• endoproteases endolytic enzymes
• Prolonged exposure to ultraviolet radiation has the effect of stimulating the expression of collagenases, particularly MMP-1. This is one of the components of photo-induced skin aging.
• One of the aims of the present invention is therefore to be able to have a product which has a collagenase inhibiting effect and if possible no significant side effects.
• Sapogenins are compounds resulting from the acid hydrolysis of saponosides, which are themselves heterosides of very high molecular weight present in the plant kingdom. These compounds have. common is a steroid structure comprising a variable number of hydroxyl and or oxo substituents and / or a variable number of double bonds. They are known as natural chemical precursors of steroid hormones and described, as such, as constituents of choice for various cosmetic or pharmaceutical preparations.
• Diosgenin has already been described as an anti-inflammatory (Yamada et al., Am. J. Physiol., 273: G355-G364, 1997) and as a slimming active by its action on adipocytes (WO 00/30603).
• the extracts of Dioscorea opposita and Dioscorea tokora, which contain diosgenin, have also been described as effective for hydrating the skin and thus softening it (JP-10 194947 and JP-2000 143488).
• the subject of the invention is the cosmetic use of at least one sapogenin or a natural extract containing it to prevent the signs of skin aging, in particular the loss of elasticity and / or of tone of the skin and / or the formation of fine lines and wrinkles, by inhibiting the activity of collagenases.
• It also relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the loss of firmness of the human skin of the face and / or the neck.
• the sapogenin used according to the invention can be chosen from: diosgenin, hecogenin, smilagenin, sarsapogenin, tigogenin, yamogenin and yuccagenin.
• Diosgenin can be extracted from tubers of wild yam by a process successively comprising: hydrolysis of the heterosides in mineral acid medium (possibly after fermentation and drying of the tubers); and filtration of the insoluble fraction, which is then neutralized, washed and treated with an apolar solvent. Other extraction methods can however be used. Diosgenin is also commercially available from SIGMA under the name Diosgenin sales representative.
• natural extracts means any plant extract containing one or more sapogenins, after any treatment intended to hydrolyze the saponosides, such as an extract of wild yam rhizome, which contains diosgenin, or an extract of leaf agave containing hecogenin and tigogenin, or an extract of Liliaceae, in particular of the genus Smilax or Yucca, containing smilagenin and sarsapogenin, such as an extract of sarsaparilla root.
• an extract of wild yam rhizome which contains diosgenin
• an extract of leaf agave containing hecogenin and tigogenin or an extract of Liliaceae, in particular of the genus Smilax or Yucca, containing smilagenin and sarsapogenin, such as an extract of sarsaparilla root.
• the natural extract used according to the invention can be obtained from plant material from a whole plant or part of a plant.
• This extract can be prepared from any plant material cultivated in vivo or in vitro.
• the term “in vivo culture” means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
• the term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
• a natural extract is used, obtained from at least one plant of the genus Dioscorea, preferably obtained from the rhizome of wild yam.
• Dioscorea belongs to the family Dioscoraceae and is made up of hundreds of species of which only a few contain sapogenins. Among these, mention may be made, for example, of Dioscorea villosa, Dioscorea opposita, Dioscorea composita, Dioscorea mexicana, Dioscorea tokora and Dioscorea floribunda.
• the extract of the invention is preferably prepared from plant material from the Dioscorea villosa and / or Dioscorea opposita species.
• Such an extract is available in particular from the company ACTIVE ORGANICS under the trade name Actigen Y ® .
• the amount of extract usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
• composition according to the invention is generally suitable for topical use and therefore it contains a physiologically acceptable medium, that is to say compatible with the skin, its integuments and / or the mucous membranes.
• This composition can be in all the galehic forms normally used in the cosmetic and dermatological fields, and it can in particular be in the form of an aqueous solution possibly gelled, of a dispersion of the lotion type possibly biphasic, of an emulsion obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of a triple emulsion (W / O / W or O / W / O) or of a vesicular type dispersion ionic and / or non-ionic.
• These compositions are prepared according to the usual methods.
• This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, in particular in the form of a stick. It can be used as a care product and / or as a make-up product for the skin.
• the composition of the invention can also contain the adjuvants usual in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matters.
• the amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition.
• These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase or into the lipid vesicles.
• these adjuvants will be chosen so as not to harm the desired properties of the sapogenins or natural extracts according to the invention.
• the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
• the oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
• the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
• oils which can be used in the invention mention may be made of mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin), oils of synthesis (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). It is also possible to use fatty alcohols (cetyl alcohol), fatty acids, waxes (carnauba wax, ozokerite).
• emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-20 stearate, and fatty acid and glycerin esters such as glyceryl stearate .
• hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
• carboxyvinyl polymers carboxyvinyl polymers
• acrylic copolymers such as acrylate / alkyl acrylate copolymers
• polyacrylamides polysaccharides
• natural gums and clays and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
• the composition also contains at least one other metalloproteinase inhibitor, such as lycopene, isoflavones, their derivatives or plant extracts containing them, in particular soy extracts (sold for example by the company ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage.
• at least one other metalloproteinase inhibitor such as lycopene, isoflavones, their derivatives or plant extracts containing them, in particular soy extracts (sold for example by the company ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage.
• the composition according to the invention may contain an agent stimulating the growth and / or metabolism of fibroblasts, such as plant proteins or polypeptides, extracted in particular from soybeans (for example a soybean extract marketed by the company LSN under the name Eleseryl SH-VEG 8 or marketed by the company SILAB under the trade name Raffermine), and / or an agent promoting the differentiation and / or growth and / or metabolism of keratinocytes, such as retinol or its derivatives or certain plant extracts such as a lupine extract marketed by the company SILAB under the trade name Structurine, and / or an agent stimulating the skin microcirculation such as a bitter orange extract sold by the company Silab under the trade name Remoduline.
• an agent stimulating the growth and / or metabolism of fibroblasts such as plant proteins or polypeptides, extracted in particular from soybeans (for example a soybean extract marketed by the company LSN under the name Eleseryl SH-VEG 8 or marketed by the company SILAB under the trade
• concentration of these optional additional agents in the composition according to the invention can vary from 0.0001 to 20% by weight and is preferably between 0.001 and 5% by weight, relative to the total weight of the composition.
• composition according to the invention may also contain an agent promoting collagen synthesis, such as ascorbic acid or its derivatives, an exfoliating agent such as ⁇ - or ⁇ -hydroxy acids, a protective agent or UV filter, an improving agent the skin barrier such as ceramides, and / or a moisturizing agent such as polyois or calcium pantothenate.
• an agent promoting collagen synthesis such as ascorbic acid or its derivatives, an exfoliating agent such as ⁇ - or ⁇ -hydroxy acids, a protective agent or UV filter, an improving agent the skin barrier such as ceramides, and / or a moisturizing agent such as polyois or calcium pantothenate.
• UV filters which are particularly suitable for use in the present invention are:
• the concentration of these UV filters in the composition according to the invention can range from 0.01 to 30% by weight, and preferably from 0.1 to 10% by weight, relative to the total weight of the composition. These filters can be used alone or in combination to obtain the desired Sun Protection Factor in the UVA and / or UVB.
• the effect of a wild yam extract on the inhibition of collagenase activity produced by Clostridium Histolyticum was evaluated. Although different from a human enzyme, this collagenase is used because of its ability to digest human collagen.
• the positive reference is phenanthroline tested at concentrations of 1 mM, 0.5 mM and 0.25 mM in ethanol.
• the used wild yam rhizome extract is an extract of the species Dioscorea villosa marketed by the company Active Organics under the trade name Actigen Y ®, which was tested at concentrations of 2%, 1%, 0.5% and 0.1% (in a test buffer consisting of collagenase at 0.125 Units / ml, Tris at 0.1 M and Ca Cl 2 at 5mM) of a stock solution at 2 mg / ml in a water / 20/80 ethanol, which corresponds to final concentrations of 40, 20, 10 and 2 ⁇ g / ml.
• the control consists of collagenase without product to be tested.
• the activity of the control constitutes 100% of collagenase activity and therefore 0% of inhibition of said activity
• the products were pre-incubated with the enzyme for 10 minutes at room temperature, then the DQ-gelatin was added and the fluorescence obtained at the degradation of the substrate was recorded for 10 minutes (excitation 485nm; emission 538nm) on a SpectraMax spectrofluorimeter (Molecular Devices); the results were processed using Soft Max Pro software.
• Example 2 Emulsion in the form of a cream
• This cream is useful, in daily applications on the face and the neck, to prevent the signs of cutaneous aging and in particular the loss of firmness of the skin.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Cosmetics (AREA)
• Medicines Containing Plant Substances (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=8857485

Family Applications (1)

Country Status (5)

Families Citing this family (20)

Family Cites Families (13)

• 2000
  • 2000-12-11 FR FR0016074A patent/FR2817747B1/fr not_active Expired - Fee Related
• 2001
  • 2001-11-26 EP EP01270315A patent/EP1351661A1/de not_active Withdrawn
  • 2001-11-26 US US10/182,730 patent/US20030152597A1/en not_active Abandoned
  • 2001-11-26 WO PCT/FR2001/003727 patent/WO2002047650A1/fr not_active Application Discontinuation
  • 2001-11-26 JP JP2002549225A patent/JP2004515523A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events